BTIG Maintains Buy Rating on Cullinan Therapeutics, Keeps $41 Target
BTIG maintained its Buy rating and $41 price target on Cullinan Therapeutics. The target implies 176.3% upside from the stock’s Oct. 27 close of $14.84.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.